Literature DB >> 26427853

Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.

Eun-Jin Bae, Na Young Yang, Cheolsoon Lee, He-Jin Lee, Seokjoong Kim, Sergio Pablo Sardi, Seung-Jae Lee.   

Abstract

Entities:  

Year:  2015        PMID： 26427853      PMCID： PMC4673478          DOI： 10.1038/emm.2015.84

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN： 1226-3613            Impact factor:   8.718


× No keyword cloud information.
  11 in total

1.  A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells.

Authors:  Matthew C Deen; Yanping Zhu; Christina Gros; Na Na; Pierre-André Gilormini; David L Shen; Sandeep Bhosale; Nadia Anastasi; RuiQi Wang; Xiaoyang Shan; Eva Harde; Ravi Jagasia; Francis C Lynn; David J Vocadlo
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-12       Impact factor: 12.779

2.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 3.  Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.

Authors:  Yvette C Wong; Dimitri Krainc
Journal:  Mov Disord       Date:  2016-09-13       Impact factor: 10.338

4.  Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Authors:  Anwesha Sanyal; Mark P DeAndrade; Hailey S Novis; Steven Lin; Jianjun Chang; Nathalie Lengacher; Julianna J Tomlinson; Malú G Tansey; Matthew J LaVoie
Journal:  Mov Disord       Date:  2020-02-08       Impact factor: 10.338

5.  Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model.

Authors:  Nicole K Polinski; Terina N Martinez; Alexander Gorodinsky; Ralph Gareus; Michael Sasner; Mark Herberth; Robert Switzer; Syed O Ahmad; Mali Cosden; Monika Kandebo; Robert E Drolet; Peter D Buckett; Weisong Shan; Yi Chen; Lee J Pellegrino; Gregory D Ellsworth; Leo B Dungan; Warren D Hirst; Sean W Clark; Kuldip D Dave
Journal:  PLoS One       Date:  2021-06-09       Impact factor: 3.240

6.  The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.

Authors:  Nicole K Polinski; Terina N Martinez; Sylvie Ramboz; Michael Sasner; Mark Herberth; Robert Switzer; Syed O Ahmad; Lee J Pelligrino; Sean W Clark; Jacob N Marcus; Sean M Smith; Kuldip D Dave; Mark A Frasier
Journal:  Dis Model Mech       Date:  2022-05-25       Impact factor: 5.732

7.  The Inhibition of miR-873 Provides Therapeutic Benefit in a Lipopolysaccharide-Induced Neuroinflammatory Model of Parkinson's Disease.

Authors:  Jinhua Wu; Xuming Yu; Ke Xue; Juan Wu; Rongyan Wang; Xianfei Xie; Ke Li; Zheqiong Yang; Jiang Yue
Journal:  Oxid Med Cell Longev       Date:  2020-07-15       Impact factor: 6.543

8.  α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies.

Authors:  Hazem Abdelkarim; Michael S Marshall; Giuseppe Scesa; Rachael A Smith; Emily Rue; Jeffrey Marshall; Vince Elackattu; Monika Stoskute; Yazan Issa; Marta Santos; Duc Nguyen; Zane Hauck; Richard van Breemen; Maria S Celej; Vadim Gaponenko; Ernesto R Bongarzone
Journal:  Sci Rep       Date:  2018-08-20       Impact factor: 4.379

Review 9.  Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.

Authors:  Christian U von Linstow; Ziv Gan-Or; Patrik Brundin
Journal:  Transl Neurodegener       Date:  2020-10-16       Impact factor: 8.014

Review 10.  Centrality of Early Synaptopathy in Parkinson's Disease.

Authors:  Paola Imbriani; Tommaso Schirinzi; Maria Meringolo; Nicola B Mercuri; Antonio Pisani
Journal:  Front Neurol       Date:  2018-03-01       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.